PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES

Guillermo Garcia-Manero; Valeria Santini; Pierre Fenaux; Takahiro Suzuki; Mikkael Sekeres; Jun He; Ronit Barkalifa; Carlos Vigil; Thomas Prebet; Rami S. Komrokji; Aristoteles Giagounidis

doi:10.1097/01.HS9.0000974868.81125.0b

Back

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES

Journal article

Peer reviewed

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES

Guillermo Garcia-Manero, Valeria Santini, Pierre Fenaux, Takahiro Suzuki, Mikkael Sekeres, Jun He, Ronit Barkalifa, Carlos Vigil, Thomas Prebet, Rami S. Komrokji, …

HemaSphere, Vol.7(Suppl)

2023-08-08

DOI: https://doi.org/10.1097/01.HS9.0000974868.81125.0b

Appears in Miller School of Medicine - Latest Publications

Abstract

Publication Only

Metrics

1 Record Views

Details

Title: PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
Creators: Guillermo Garcia-Manero - MD Anderson Cancer Center, Houston, TX, United States
Valeria Santini - University of Florence
Pierre Fenaux - Assistance Publique – Hôpitaux de Paris
Takahiro Suzuki - Kitasato University
Mikkael Sekeres - University of Miami
Jun He - Bristol Myers Squibb, Summit, NJ, United States
Ronit Barkalifa - Bristol Myers Squibb, Summit, NJ, United States
Carlos Vigil - Bristol-Myers Squibb
Thomas Prebet - Bristol-Myers Squibb
Rami S. Komrokji - Moffitt Cancer Center
Aristoteles Giagounidis - Marien Hospital Düsseldorf
Publication Details: HemaSphere, Vol.7(Suppl)
Publisher: Lippincott Williams & Wilkins
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031926772602976